Cervical Cancer Vaccine has limited Benefits in Older Women

A novel study indicated that women over forty years of age are not likely to garner benefits to a large extent from inoculation for the virus causing cervical cancer.

Immunization for HPV (human papillomavirus), is advised for all women up to twenty-six years of age and even for girls of nine years of age. The latest study headed by author Dr. Ana Cecilia Rodriguez stated that the study was conducted for ascertaining if women in the older age band could be shielded alongside observing outline of HPV infection as women grew older.

The study did a follow-up of over nine thousand women from Costa Rica in the age group of nineteen to 97 years and screened them for cancer-causing HPV infections and originators to cervical cancer.

The study that was lately released online in The Journal of the National Cancer Institute showed that the rate of lately identified infections plummeted as women aged – to 13.5% among women forty-two years and more, from thirty-five percent among women in ages 18-25 years. New-fangled infections were observed to usually subside in analogous manner among both older and younger females with no need for treatment.

Dr. Rodriguez expounded that despite cervical cancer having far greater prevalence among older-aged women as compared to women in the younger age group; it has been observed to develop decade or more time periods following the preliminary infection with a cancer-causing virus.

Dr. Rodriguez from the Inceinsa Foundation, a fitness and nutrition organization, whose effort was backed by the NIH (National Institutes of Health) in the U.S. stated that as the HPV vaccine could solely avert infections, and since such women were not contracting infections to that vast an extent, hence likely gains from the HPV inoculation in women from the older age group was quite circumscribed.

Popularity: 4% [?]